R&D Trends

CRT, Merck to develop inhibitors for cancer and blood disorders

Tuesday, February 2, 2016

Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research U.K., has entered into a license agreement with MSD, known as Merck in the U.S. and Canada, to develop inhibitors of protein arginine methyltransferase 5 (PRMT5). These new drugs, which potentially have clinical applications in both cancer and non-cancer blood disorders, have been developed by the Australian Cooperative Research Center (CRC) for Cancer Therapeutics (CTx) with support from the Wellcome Trust and CRT.​

[Read More]

Codiak BioSciences closes $61M series B financing

Thursday, January 28, 2016

Codiak BioSciences Inc., a leading company in the field of exosome biology, announced the closing of its $61 million Series B round, bringing total investment in its combined Series A and B financing, announced in November 2015, to $92 million. Codiak intends to use the proceeds of this round primarily to advance research and clinical development of exosomes for therapeutic and diagnostic purposes. 

[Read More]